Sophie Rigaudeau

1.4k total citations
22 papers, 558 citations indexed

About

Sophie Rigaudeau is a scholar working on Genetics, Hematology and Infectious Diseases. According to data from OpenAlex, Sophie Rigaudeau has authored 22 papers receiving a total of 558 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 8 papers in Hematology and 7 papers in Infectious Diseases. Recurrent topics in Sophie Rigaudeau's work include Chronic Lymphocytic Leukemia Research (8 papers), Acute Myeloid Leukemia Research (5 papers) and Acute Lymphoblastic Leukemia research (5 papers). Sophie Rigaudeau is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Acute Myeloid Leukemia Research (5 papers) and Acute Lymphoblastic Leukemia research (5 papers). Sophie Rigaudeau collaborates with scholars based in France, United Kingdom and United States. Sophie Rigaudeau's co-authors include Philippe Rousselot, Sylvie Castaigné, Christine Terré, H. Farhat, Juliette Lambert, N. Baron, Jean‐Louis Georges, B. Livarek, Thierry de Revel and Norbert Vey and has published in prestigious journals such as Blood, European Journal of Cancer and British Journal of Haematology.

In The Last Decade

Sophie Rigaudeau

21 papers receiving 550 citations

Peers

Countries citing papers authored by Sophie Rigaudeau

Since Specialization

Citations

This map shows the geographic impact of Sophie Rigaudeau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sophie Rigaudeau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sophie Rigaudeau more than expected).

Fields of papers citing papers by Sophie Rigaudeau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sophie Rigaudeau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sophie Rigaudeau. The network helps show where Sophie Rigaudeau may publish in the future.

Co-authorship network of co-authors of Sophie Rigaudeau

This figure shows the co-authorship network connecting the top 25 collaborators of Sophie Rigaudeau. A scholar is included among the top collaborators of Sophie Rigaudeau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sophie Rigaudeau. Sophie Rigaudeau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma 2022 ·Journal of Oncology Pharmacy Practice ·María‐Victoria Mateos, Sophie Rigaudeau, Supratik Basu, Ivan Špıčka, Rik Schots, Tomasz Wróbel, Gordon Cook, Meral Beksaç, Katharine S. Gries, Anupa Kudva, Brenda Tromp, Rian Van Rampelbergh, Huiling Pei, Susan Wróblewski, Robin Carson, Maria Delioukina, Darrell White	10
2	A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia 2021 ·Haematologica ·Milena Kohn, Marc Delord, (unknown), (unknown), Fatiha Merabet, (unknown), (unknown), H. Farhat, (unknown), Aurélie Cabannes‐Hamy, Juliette Lambert, Stéphanie Marque‐Juillet, Victoria Raggueneau, (unknown), Marc Spentchian, Sophie Rigaudeau, Philippe Rousselot, Caroline Besson	10
3	A Third Anti-Sars-Cov2 mRNA Dose Does Not Overcome the Pejorative Impact of Anti-CD20 Therapy and/or Low Immunoglobulin Level in CLL/Lymphoma Patients 2021 ·Blood ·(unknown), Milena Kohn, Fatiha Merabet, (unknown), (unknown), (unknown), Stéphanie Marque‐Juillet, Victoria Raggueneau, (unknown), Marc Spentchian, Marc Delord, Sophie Rigaudeau, Caroline Besson	1
4	Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature 2019 ·British Journal of Haematology ·(unknown), Alexis Talbot, (unknown), Stéphanie Harel, Lionel Galicier, Agnès Veyradier, Bérangère S. Joly, Annalisa Andreoli, Sophie Rigaudeau, Élie Azoulay, Paul Coppo, Bruno Royer, Bertrand Arnulf	7
5	Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia 2017 ·Leukemia & lymphoma ·(unknown), (unknown), David Ghez, Pascale Cony‐Makhoul, (unknown), (unknown), (unknown), (unknown), (unknown), H. Farhat, Sophie Rigaudeau, Noémie de Gunzburg, (unknown), Christine Terré, Victoria Raggueneau, (unknown), Marc Spentchian, Stéphane de Botton, Philippe Rousselot	15
6	The Plasmair Decontamination System Is Protective Against Invasive Aspergillosis in Neutropenic Patients 2016 ·Infection Control and Hospital Epidemiology ·(unknown), Anne‐Sophie Jannot, Sophie Rigaudeau, Juliette Lambert, O. Éloy, François Mignon, H. Farhat, Sylvie Castaigné, Jacques Merrer, Philippe Rousselot	2
7	Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity 2016 ·European Heart Journal - Cardiovascular Imaging ·(unknown), (unknown), Sophie Rigaudeau, (unknown), N. Baron, Juliette Lambert, (unknown), Jean‐Louis Georges, H. Farhat, Jérôme Lambert, Philippe Rousselot, B. Livarek	74
8	Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy for the prediction of subsequent cardiotoxicity 2016 ·Annales de Cardiologie et d Angéiologie ·(unknown), (unknown), Sophie Rigaudeau, A.-L. Taksin, N. Baron, Juliette Lambert, (unknown), Jean‐Louis Georges, H. Farhat, Philippe Rousselot, B. Livarek	40
9	Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis 2013 ·European Journal of Cancer ·David Ghez, Jean‐Baptiste Micol, Florence Pasquier, Nathalie Auger, Véronique Saada, Marc Spentchian, Jean‐Christophe Ianotto, Jean Bourhis, (unknown), Christine Terré, Sylvie Castaigné, Sophie Rigaudeau, Philippe Rousselot, Stéphane de Botton	16
10	Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse 2013 ·American Journal of Hematology ·Sylvain Pilorge, Sophie Rigaudeau, Florence Rabian, Clémentine Sarkozy, (unknown), H. Farhat, (unknown), (unknown), Victoria Raggueneau, Christine Terré, (unknown), Aline Renneville, Claude Preudhomme, Sylvie Castaigné, Philippe Rousselot	19
11	False positive galactomannan Platelia due to piperacillin-tazobactam 2011 ·Médecine et Maladies Infectieuses ·(unknown), Philippe Rousselot, Sophie Rigaudeau, (unknown), Sophie Touratier, Sylvie Castaigné, O. Éloy	31
12	Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia 2011 ·Blood ·Bob Löwenberg, Petra Muus, Gert J. Ossenkoppele, Philippe Rousselot, Jean‐Yves Cahn, Norbert Ifrah, Giovanni Martinelli, Sergio Amadori, Ellin Berman, Pieter Sonneveld, Mojca Jongen‐Lavrencic, Sophie Rigaudeau, Paul K. Stockman, (unknown), Stefan Faderl, Elias Jabbour, Hagop M. Kantarjian	96
13	Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS 2009 ·Clinica Chimica Acta ·Olivia Roth, Odile Spreux‐Varoquaux, Stéphane Bouchet, Philippe Rousselot, Sylvie Castaigné, Sophie Rigaudeau, Victoria Raggueneau, Patrice Thérond, Philippe Devillier, Mathiéu Molimard, Benjamin Manéglier	62
14	Évaluation de la quantification du cytomégalovirus dans le sang par le test de PCR en temps réel CMV R-gene® 2009 ·Pathologie Biologie ·Stéphanie Marque‐Juillet, (unknown), (unknown), (unknown), A. Therby, Sophie Rigaudeau, M Harzic	1
15	Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia 2008 ·Haematologica ·(unknown), A. Etienne, Pascal Turlure, Thierry de Revel, X. Thomas, Nathalie Contentin, Christine Terré, Sophie Rigaudeau, Dominique Bordessoule, Norbert Vey, Claude Gardin, Hervé Dombret	106
16	Outcome of Relapsed AML Patients Aged between 50 and 70: The ALFA Group Experience (ALFA 9801 Study). 2007 ·Blood ·Fatiha Merabet, Nicolas Boissel, Oumédaly Reman, Jean Bourhis, Bruno Quesnel, Sophie Rigaudeau, C. Cordonnier, Dominique Bordessoule, H Tilly, Sélim Corm, Mauricette Michallet, (unknown), Xavier Thomas, Sylvie Chevret, Pierre Fenaux, Sylvie Castaigné	2
17	Syndrome respiratoire aigu sévère (SRAS) 2006 ·P Bossi, Amélie Guihot, Sophie Rigaudeau, Sophie Bouvresse, François Bricaire	0
18	Les virus des encéphalites virales, une nouvelle menace bioterroriste 2005 ·La Presse Médicale ·Sophie Rigaudeau, Romain Micol, François Bricaire, Philippe Bossi	1
19	Risque de variole, vaccination et bioterrorisme 2005 ·La Presse Médicale ·P Bossi, D. Garín, Christophe Combadière, Étienne Rouleau, Sophie Rigaudeau, Bénédicte Lebrun‐Vignes, (unknown), Brigitte Autran, François Bricaire	2
20	Fièvres hémorragiques virales, possibilité d’utilisation bioterroriste 2005 ·La Presse Médicale ·Sophie Rigaudeau, François Bricaire, (unknown)	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact